Vaccines against pathogens can cut global antibiotic usage by 22%
Vaccines against 24 pathogens could cut the number of antibiotics needed to fight antimicrobial resistance by 2.5 billion daily doses or 22% globally,.
Drugs
Health
Pharma
Drugs
Health
Pharma
Skin care products with benzoyl peroxide can turn carcinogenic
HQ Team October 10, 2024: A recent study has raised concerns about the safety of topical benzoyl peroxide (BPO) products used for treating.
Drugs
Health
Pharma
Researchers find new tech to change IV therapies into oral pills
HQ Team October 10, 2024: A study published in Nature Communications discusses a novel water-soluble prodrug technology called Sol-moiety, which enhances the oral bioavailability of.
Climate
Drugs
Medical
Baxter plans to limit stockpiling of its drugs after Hurricane Helene
US-based Baxter International Inc., is implementing an allocation policy to limit stockpiling of its drugs after Hurricane Helene ripped through its facility in.
Drugs
Health
Pharma
GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.
Drugs
Health
Pharma
Sage Therapeutics halts trials of experimental drug to treat dementia
Sage Therapeutics Inc.’s experimental drug failed to meet its main goal of treating mild dementia due to Alzheimer's disease and the US, Cambridge-headquartered.
Drugs
Health
Medical
J&J stops trials on drug to treat muscle-invasive bladder cancer
Johnson and Johnson discontinued a study of an investigational drug to treat bladder cancer after it failed to yield desired results
Drugs
Health
Medical
Balancing gut bacteria can reduce inflammation in rheumatoid arthritis
HQ Team October 7, 2024: Rheumatoid arthritis (RA), an autoimmune disease that causes joint and bone inflammation, is affected by gut bacteria. Researchers.
Drugs
Health
Medical
UK’s DIOSynVax develops single candidate vaccine for bird flu virus
UK-based DIOSynVax, a biotechnology company, has developed a single candidate vaccine neutralizing immune responses across the spectrum of very diverse H5 subtypes of influenza.
Drugs
Health
Pharma
US drug regulator clears Qnovia’s nicotine inhaler for clinical testing
HQ Team October 7, 2024: The US Food and Drug Administration (FDA)has cleared Qnovia Inc’s nicotine inhaler RespiRx for clinical trial. The US.